HSP90AB1 and neoplasm: Moreover, combining Hsp90 inhibitors, such as 17-DMAG, with adoptive cellular immunotherapy, including cytokine-induced killer (CIK) cells, has been shown to significantly enhance therapeutic T cell responses and overcome tumor resistance [151,152].